Antibiotic-resistant infections are predicted to kill 10 million people worldwide per year 14 by 2050 and to cost the global economy 100 trillion USD. Novel approaches and 15 alternatives to conventional antibiotics are urgently required to combat antimicrobial 16 resistance. We have synthesized a chitosan-based oligolysine antimicrobial peptide, 17 CSM5-K5, which targets multidrug resistant (MDR) bacterial species. Here we show 18 that CSM5-K5 exhibits rapid bactericidal activity against methicillin resistant 19 Staphylococcus aureus (MRSA), MDR Escherichia coli, and vancomycin resistant 20 Enterococcus faecalis (VRE). Combinatorial therapy of CSM5-K5 with antibiotics to 21 which each organism is otherwise resistant restores sensitivity to the conventional 22 antibiotic. CSM5-K5 alone significantly reduced pre-formed bacterial biofilm by two-four 23 orders of magnitude and, in combination with traditional antibiotics, reduced pre-formed 24 biofilm by more than two-three orders of magnitude at sub inhibitory concentrations.
of bacteria were diluted to between 10 5 to 10 6 CFU/mL in fresh MHB (for E. faecalis TSB 144 with 0.25% glucose was used to achieve optimal growth), and 150 μL was transferred to 145 the wells of a MBEC microtiter plate (Innovotech, Canada) were executed for each of these assays.
156
Antimicrobial resistance evolution assay 157 We asseessed resistance development of bacterial strains by sequential passaging 158 each strain in the presence of sub-inhibitory concentrations of the cationic peptide 159 polymer, CSM5-K5, or conventional antibiotics, essentially as previously described (17). 160 In brief, bacterial cells were grown at 37°C in MH broth with shaking to mid-log phase 161 and diluted to 1-5  10 5 CFU/mL in MH broth containing 0.25, 0.5, 1, 2 and 4 MIC (Table S1 ) and then tested for synergy between 240 CSM5-K5 and antibiotics which each organism was resistant to using a checkerboard 241 assay containing two-fold dilutions for each compound. CSM5-K5 displayed partial 242 synergy with oxacillin, meropenem, and other antibiotics against S. aureus USA300, 243 with a fractional inhibitory concentration index (FICI) >0.5 to ≤0.1 ( Table S2 and sensitivity to MICs of 4 and 2 µg/mL, respectively (Fig. 1C, data not shown) .
Furthermore, CSM5-K5 exhibited potent synergy with the aminoglycosides streptomycin 253 and tetracycline against E. coli EC958 (FICI <0.5) ( Fig. 1D, data not shown) . The MICs 254 for E. coli EC958 for both streptomycin and tetracycline are 32 µg/mL (Table S1) . 255 However, CSM5-K5 (0.25 MIC) is synergistic with streptomycin and tetracycline at 256 concentrations of ≤8 µg/mL, bringing the MICs to 8 and 4 µg/mL respectively (data not 257 shown).
259
For all of the antibiotics we tested in combination with CSM5-K5, we observed reduction 260 of the antibiotic MIC into the clinical therapeutic range for each bacterial species (14). 261 We confirmed synergistic interactions using time killing curve assays and demonstrated 262 that combinatorial bactericidal action occurred within synergistic concentrations of 263 CSM5-K5 and respective antibiotics against each bacterial species. For E. coli EC958, 264 we observed a more than two-log reduction within 5 hours of CSM5-K5 exposure at 265 sub-MIC concentrations of 0.25 MIC and 0.37 MIC, with aminoglycosides 266 streptomycin or tetracycline at 0.125 MIC or 0.25 (Fig. S1A, B) . By contrast, higher 267 concentrations of either individual antibiotic resulted in an initial drop in CFU followed by 268 recovery by 5 hours and growth of the culture. Similarly, we observed a more than two-269 log reduction of E. faecalis V583 within 5 hours with combinatorial sub-MIC 270 concentrations of CSM5-K5 and vancomycin or oxacillin ( Fig. S1C, D) . Moreover, we 271 observed bactericidal action against S. aureus USA 300 at sub-MIC concentrations of 272 CSM5-K5 of 0.5 with 0.03 MIC oxacillin and 0.06 MIC meropenem (Fig. S1E, F) . with antibiotics had synergistic bactericidal activity against biofilm, similar to that 281 observed for planktonic bacteria. We therefore performed a minimum biofilm eradication 282 concentration (MBEC) assay in which we exposed pre-formed 27-28 hour biofilms to 283 CSM5-K5 in the absence or presence of a conventional antibiotic for 3-4 hours.
284
Exposure of S. aureus USA300, E. faecalis V583, or E. coli EC958 to 1 MIC of CSM5-285 K5 resulted in an approximately three, two, or four-log reduction, respectively, for each 286 of the organisms, representing >99% reduction in biofilm bacteria after just 4 hours of 287 treatment compared to the untreated controls ( Fig. 2A) .
289
We observed for biofilms that, as for planktonic bacteria, CSM5-K5 was synergistic with 290 conventional antibiotics at concentrations well below the MIC of each resistant strain.
291
For example, CSM5-K5 displayed an antibiotic-enhancing effect for oxacillin and 292 meropenem against S. aureus USA300 pre-formed biofilms at sub inhibitory 293 concentrations of each. CSM5-K5 increased oxacillin biofilm reduction by 3-4.5 orders 294 of magnitude compared with untreated biofilm, and 1.9-3.3 orders of magnitude 295 compared to either of their single agent treatment alone (Fig. 2B) . CSM5-K5 in 296 combination with meropenem displayed an even higher efficacy for biofilm reduction, with 3.5-5.3 and 2-4 orders of magnitude reduction in CFU compared to untreated 298 controls and single agent treatment, respectively (Fig. 2B) . Similarly, we observed E. coli EC958 biofilm (Fig. 2D) .
311
In vivo combined efficacy of CSM5-K5 with clinically relevant antibiotics 312 We next tested the ability of CSM5-K5 alone and in combination with conventional 313 antibiotics to treat biofilm infections in a murine excisional wound infection model.
314
Excisional wounds were infected with ~10 3 CFU of each bacterial species, and then µg/mL for S. aureus USA300 and E. faecalis V583, respectively) resulted in greater than 320 90% reduction of USA300 and V583 CFU, compared to untreated controls (Fig. 3A) . 321 Treatment of E. coli EC958 with 1 MIC of CSM5-K5 resulted in >99% killing and a >3 322 log reduction in CFU compared to the untreated control (Fig. 3A) . While combinatorial 323 treatment did not further reduce S. aureus CFU at the concentrations tested in this 324 experiment compared to CSM5-K5 alone (Fig. 3A) , treatment of E. faecalis and E. coli 325 infected wounds with sub-inhibitory concentrations of CSM5-K5 together with sub-326 inhibitory concentrations of antibiotics significantly improved bacterial killing compared 327 to either single agent treated or untreated control (Fig. 3C, D) with sub-inhibitory concentrations of CSM5-K5 (Fig. 4) . By contrast, serial passaging of 342 S. aureus USA300 at sub-inhibitory concentrations of rifampicin, vancomycin, or gentamicin resulted in antibiotic resistance that was more than four-fold higher than the 344 initial MIC (Fig. 4A) . Similarly, MICs of rifampicin, tetracycline and meropenem were 345 more than four-fold higher in E. faecalis V583 after 15 days of co-culture with the 346 antibiotic (Fig. 4B) . In E. coli EC958, resistance of 7, 6 and 3 times higher than the 347 original MIC was observed for gentamicin, meropenem and polymyxin B, respectively 348 (Fig. 4C) . The failure to obtain CSM5-K5 resistance levels more than two-fold higher 349 than their initial MIC values suggest a non-specific mode of action. faecalis V583, we sequenced 5 isolates from each of two independent serial passage 356 experimental evolution assays (10 isolates in total) isolated at day 6 when the CSM5-K5
357
MIC was 64 µg/ml (1 MIC). Using a threshold variant frequency cut-off of >35%, we 358 found that resistant mutants contained a diverse set of mutations (Table S3) . At day 6, 359 we observed independent mutations in genes encoding ATP synthase machinery in 6 of 360 10 mutants (Table S3, Fig. 4B) . We validated this finding by assessing the MIC for E. 361 faecalis transposon mutants in the respective genes in strain OG1RF (atpE, atpE2, and 362 atpG), which all displayed a 2-fold higher MIC for CSM5-K5 ( S3, Fig. 4A ). We identified a diverse array of mutations, including which could be contributing to the mechanism of CSM5-K5 resistance.
386
Restored oxacillin susceptibility in CSM5-K5 R USA300 isolates. 387 In an attempt to understand why we observed enhanced oxacillin susceptibility after S.
388
aureus co-incubation with CSM5-K5 and oxacillin, we reanalyzed the same CSM5-K5 R 389 mutants with a reduced threshold variant frequency of <35% and observed mutations in 390 the ebh gene encoding hyperosmolarity resistance protein Ebh in nine isolates, which is 391 associated with susceptibility to the β-lactam antibiotic oxacillin (29) ( tested (Table S6) . Similarly, CSM5-K5 R did not confer cross resistance to any other 398 antibiotic for either E. faecalis or E. coli (Table S6 ). Finally, we selected and evaluated 399 whether CSM5-K5 R mutant 11 conferred oxacillin susceptibility to this otherwise oxacillin 400 resistant strain both in vitro and in vivo models. We observed that CSM5-K5 R mutant 11 401 exhibited oxacillin susceptibility at MIC 2 µg/mL (Fig. 5A) . Similarly, we observed a 402 significant difference between mutant and wild type growth when treated with oxacillin 403 as well as with CSM5-K5 ( Fig. 5B) nanoparticles synergistically cluster anionic membrane lipids and produce a greater 438 membrane perturbation and antibacterial effect than would be achievable by the same 439 quantity of charge if dispersed in individual copolymer molecules in solution (12). We 440 observed partial of full antimicrobial synergy, against both Gram-negative and Gram-441 positive pathogens, between CSM5-K5 and nearly every antibiotic that we tested. We
442
propose that the membrane-perturbing action of CSM5-K5 enables increased uptake 443 and/or access of each antibiotic to its target. In this study, this synergy could be 444 achieved at antibiotic concentrations to which the MDR pathogens were otherwise 445 resistant. These observations suggest that this may be true for any antimicrobial 446 resistant organism, regardless of the resistance mechanism or antibiotic mechanism of 447 action. Together, the data in this manuscript present a viable combinatorial treatment 448 strategy for difficult to treat antibiotic tolerant biofilm-associated infections, as well as 449 those with genetically encoded resistance to traditional antibiotics, with minimal risk of 450 antimicrobial resistance. We are grateful to Jenny Dale and Gary Dunny for supplying us with E. faecalis OG1RF 454 transposon mutants used in this study. This work was supported by the National
